Global Oncology Drug Market Size, Share, Analysis, Trends, Growth, Forecasts 2032

What is the oncology drug market size?

The size of the global oncology drug market was estimated to be approximately $146.9 billion in 2023 and is anticipated to reach $473.1 billion by 2032, represented by a projected compound annual growth rate of 14.0%.

Request Free Sample

Oncology Drug Market Overview

Cancer is a class of chronic illness characterized by uncontrolled cell growth. The common types of cancer are breast cancer, cancer of the lung, colorectal cancer, uterine cancer and cancer of the thyroid. The three main drugs used for cancer are cytotoxic drugs, targeted drugs, and hormonal drugs based on their mechanism of action. The investment dynamics has increased which has propelled the growth for oncology rug market.

Oncology is a branch of therapeutic science that study malignancy and treatment and prevention of malignancy. Segments of oncology include radiation oncology (the use of radiation therapy to treat cancer), medical oncology (the use of chemotherapy, hormone therapy and other drugs to treat cancer), and surgical oncology (the use of surgeries to treat cancer).

Cancer is the uncontrolled growth of abnormal cells anywhere in an individual’s body. These cells are termed as tumor cells or malignant cells. Frequently, cancer cells can detach from this original mass of cells, travel along the blood and lymph systems, and lodge in other organs where they can repeat the uncontrolled growth cycle. This process of cancer cells, leaving an area and growing in another area of the body is termed as metastatic spread or metastasis.

Cancer stage is often determined by biopsy results which also helps to determine the cancer type and the extent to which cancer has spread in an individual. Staging also helps doctors to determine treatment protocols. 

Oncology Drug Market: Market Dynamics

Major drivers in the oncology drug market include growing prevalence of various types of cancer, increasing demand of biological and targeted drug therapies, technological advancements in the healthcare sector, continuous patent expiry of key cancer drugs, rise in need for R&D activities in cancer, growing concerns over high death rates due to cancer and the rising impact of biosimilars.

The threat of failure and the adverse effects of cancer drug therapy; particularly chemotherapy, strict government regulations, the high cost of drug development is expected to hinder the growth of the global oncology drugs market over the forecast period.

Oncology treatments are rapidly evolving with the latest innovations emerging from immunotherapy research, thus creating new grounds for R&D for the competing firms, cancer vaccines is also seeing a genetic engineering of living immune cells and reinfusing them into cancer patients, re-emerged when combined with checkpoint inhibitors, yet another kind of immunotherapy, is swiftly advancing. The recent discovery of genes linked to ovarian cancer risk (RAD51C and RAD51D0), new pancreatic cancer susceptibility genes (CDKN2A, BRCA1/2, PALB2), and the discovery that many cases of pediatric cancer are associated with hereditary gene mutations, may lead to new kinds of targeted therapies.

Request Free Sample

Oncology Drug market: Report Scope

Segmentation based on Regions:

North America dominates the oncology drug market over the forecast period, attributed to high presence of the cancer drugs development companies in the U.S. Additionally, high disposable incomes of consumers and compulsory health insurance cover for life-threatening diseases leads to increasing the affordability of cancer treatment in the U.S. Europe is the second largest revenue generating region in oncology drugs market over the forecast period.  The research for cancer drugs in developing economies including Asia Pacific, Latin America, and the Middle East and Africa is emerging with the focus towards the development of biosimilars. The prevalence of various cancer types is high in developing countries which generates interest for these regions to conduct clinical trials. In addition, the cost of research is low in these regions due to favorable government policies and the availability of a huge population base contributing to the oncology drug market growth in the developing countries. This, in turn, results in the significant growth of oncology drug market in the developing region over the forecast period.

Oncology Drug Market: Competitors

Some of the key players in the global oncology drug market include

• Johnson & Johnson
• Amgen Inc.
• Eli lilly & Co.
• GlaxoSmithKline
• Roche diagnostics
• Merck & Co.
• Pfizer
• Sanofi
• Celgene Corporation
• and Novartis AG.

The report segments of the Oncology Drug market into:

By Therapeutic Modals

• Chemotherapy
• Targeted therapy
• Immunotherapy
• Hormonal therapy
• Others

By Cancer Type

• Breast cancer
• Blood cancer
• Prostate cancer

By Gastrointestinal tract cancer

• Skin cancer
• Lung cancer
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.